کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3052505 | 1579931 | 2010 | 5 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population](/preview/png/3052505.png)
SummaryAntiepileptic drugs including lamotrigine (LTG) and carbamazepine (CBZ) are among the most common causes of cutaneous adverse reactions (cADRs). Human leukocyte antigen (HLA)-B*1502 has been strongly associated with CBZ-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). To investigate this relationship, we performed high-resolution HLA genotyping on LTG-tolerant controls, healthy volunteers, and patients affected by LTG-induced cADRs, ranging from maculopapular exanthema (MPE) to SJS/TEN. Patients with LTG-induced cADRs (n = 25, including three with SJS/TEN and 22 with MPE), 21 LTG-tolerant controls, and 71 healthy volunteers were enrolled. The differences in the starting dosage of LTG among the SJS/TEN, MPE, and LTG-tolerant control groups were not statistically significant. HLA-B*1502 frequency was 33.3% (1/3; LTG-induced SJS/TEN group), 9.1% (2/22; LTG-induced MPE group), 4.8% (1/21; LTG-tolerant group), and 8.5% (6/71; healthy volunteers). There was no significant difference in the frequency of subjects with the HLA-B*1502 allele between the SJS/TEN group and LTG-tolerant group (p = 0.239, OR = 10.0, 95% CI 0.44–228.7), and healthy volunteers (p = 0.26, OR = 5.42, 95% CI 0.43–68.8), MPE and LTG-tolerant groups (p = 1.0, OR = 1.08, 95% CI 0.20–5.8), and healthy volunteers (p = 1.0, OR = 2.0, 95% CI 0.17–23.9). None of the HLA alleles detected were associated with LTG-induced cADRs. In conclusion, HLA-B*1502 and other HLA alleles are not directly associated with LTG-induced MPE. The possibility that HLA-B*1502 is associated with an increased risk of LTG-induced SJS/TEN could not be excluded.
Journal: Epilepsy Research - Volume 92, Issues 2–3, December 2010, Pages 226–230